HCV drug from Gilead shows efficacy in late-stage trial

02/20/2013 | Yahoo

Patients with certain genotypes of hepatitis C who took Gilead Sciences' sofosbuvir in a late-stage clinical trial had cure rates of 50% at 12 weeks and 73% at 16 weeks, compared with the 25% historic cure rate among such patients. Sofosbuvir-treated patients with cirrhosis showed lower sustained virologic response, researchers said.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ